文献速递静脉血栓栓塞

癌症患者静脉血栓栓塞抗凝治疗疗效与安全性的系统评价与荟萃分析

Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2019-01-01

低分子肝素较维生素K拮抗剂更有效预防复发VTE和深静脉血栓,直接口服抗凝药较VKA更有效预防复发VTE,但直接口服抗凝药较低分子肝素更有效预防复发VTE却增加大出血风险。

要点

  • 低分子肝素较维生素K拮抗剂更有效预防癌症患者复发VTE和深静脉血栓。
  • 直接口服抗凝药较维生素K拮抗剂更有效预防复发VTE,但大出血风险需关注。
  • 直接口服抗凝药较低分子肝素更有效预防复发VTE,但大出血风险更高。

核心结论

  • 与维生素K拮抗剂相比,低分子肝素和直接口服抗凝药治疗癌症患者VTE更有效,但低分子肝素出血更少。
  • 直接口服抗凝药较低分子肝素更有效预防VTE复发,但可能增加大出血风险,需等待正在进行的试验提供更多信息。

研究设计与样本

  • 系统评价与荟萃分析,2018年5月17日检索MEDLINE和Scopus数据库的随机对照试验。
  • 主要结局为复发VTE(疗效)和出血事件(安全性),以风险比(RR)及95%置信区间(CI)表示,采用GRADE方法评估证据质量。

主要发现

  • 低分子肝素较维生素K拮抗剂更有效预防复发VTE(RR 0.58,95% CI 0.45-0.75)和深静脉血栓(RR 0.44,95% CI 0.29-0.69),但对肺栓塞、出血或总死亡率无差异。
  • 直接口服抗凝药较维生素K拮抗剂更有效预防复发VTE(RR 0.65,95% CI 0.45-0.95),但对深静脉血栓、肺栓塞、总死亡率或出血无差异。
  • 抗Xa因子直接口服抗凝药较维生素K拮抗剂更有效(VTE的RR 0.64,95% CI 0.42-0.97)且出血更少,但大出血仅在无需初始肠外抗凝的直接口服抗凝药中减少(RR 0.45,95% CI 0.21-0.97)。
  • 直接比较中,直接口服抗凝药较低分子肝素更有效预防VTE复发(RR 0.64,95% CI 0.45-0.90)但大出血更多(RR 1.75,95% CI 1.10-2.77),致命性出血和总死亡率无差异。
  • 证据质量在充分时多为中等或高。

关键数值与推荐

  • 低分子肝素 vs 维生素K拮抗剂:复发VTE的RR 0.58(95% CI 0.45-0.75),深静脉血栓的RR 0.44(95% CI 0.29-0.69)。
  • 直接口服抗凝药 vs 维生素K拮抗剂:复发VTE的RR 0.65(95% CI 0.45-0.95)。
  • 抗Xa因子直接口服抗凝药 vs 维生素K拮抗剂:VTE的RR 0.64(95% CI 0.42-0.97);无需初始肠外抗凝的直接口服抗凝药大出血的RR 0.45(95% CI 0.21-0.97)。
  • 直接口服抗凝药 vs 低分子肝素:VTE复发的RR 0.64(95% CI 0.45-0.90),大出血的RR 1.75(95% CI 1.10-2.77)。

临床怎么用

  • 癌症患者VTE抗凝治疗中,低分子肝素较维生素K拮抗剂更有效预防复发且出血更少。
  • 直接口服抗凝药可作为维生素K拮抗剂的替代,但需权衡大出血风险,尤其较低分子肝素时。
  • 抗Xa因子直接口服抗凝药可能提供更好的疗效与出血平衡,但需个体化评估。

局限性

  • 证据质量在充分时多为中等或高,但部分结局证据可能有限。
  • 直接口服抗凝药较低分子肝素的大出血风险增加需进一步试验确认。
  • 研究检索截至2018年5月,可能未纳入后续新证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/BACKGROUND: The aim was to review the relative efficacy and safety of anticoagulation for managing venous thromboembolism (VTE) in patients with cancer. METHODS: A systematic review and meta-analysis was carried out. On 17 May 2018 the MEDLINE and Scopus databases were searched for randomised controlled trials (RCTs). Eligible RCTs had to be performed in patients with cancer exclusively or to report results on a subset of patients with cancer. The main study outcomes (efficacy/recurrent VTE and safety/bleeding events) were expressed as risk ratios (RR) with a 95% confidence interval (CI). The quality of evidence was assessed following the GRADE method. RESULTS: Twenty-three RCTs with 6980 patients were identified. Low molecular weight heparins (LMWHs) were more effective than vitamin K antagonists (VKAs) in preventing recurrent VTE (RR 0.58, 95% CI 0.45-0.75) and deep vein thrombosis (RR 0.44, 95% CI 0.29-0.69) but not pulmonary embolism (PE), bleeding, or overall mortality. Direct oral anticoagulants (DOACs) were more effective than VKAs in preventing recurrent VTE (RR 0.65, 95% CI 0.45-0.95) but not DVT, PE, overall mortality, or bleeding. However, anti-Xa DOACs were more effective (RR for VTE 0.64, 95% CI 0.42-0.97) and caused less bleeding than VKAs, although major bleeding was reduced only with DOACs not requiring initial parenteral anticoagulation (RR 0.45, 95% CI 0.21-0.97). In a direct comparison, DOACs were more effective than LMWHs in preventing VTE recurrence (RR 0.64, 95% CI 0.45-0.90) but caused more major bleeding (RR 1.75, 95% CI 1.10-2.77), with no difference in fatal bleeding and overall mortality. Quality of evidence, where sufficient, was mostly moderate or high. CONCLUSION: Compared with VKAs, LMWHs and DOACs are more effective in treating VTE, but the former caused less bleeding. DOACs are more effective than LMWHs in preventing VTE recurrence but may carry a higher risk of major bleeding, pending additional information by ongoing trials.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kirkilesis GI, Kakkos SK, Tsolakis IA, et al. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer. Eur J Vasc Endovasc Surg. 2019. PMID: 31097186. doi:10.1016/j.ejvs.2018.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。